These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 7168557)

  • 1. Effect of tamoxifen treatment on estrogen metabolism in postmenopausal women with advanced breast cancer.
    Levin J; Markham MJ; Greenwald ES; O'Connor JF; Zumoff B; Fukushima DK
    Anticancer Res; 1982; 2(6):377-80. PubMed ID: 7168557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between urine and plasma estrogen ratios.
    Longcope C; Pratt JH
    Cancer Res; 1978 Nov; 38(11 Pt 2):4025-8. PubMed ID: 698950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of tamoxifen on testosterone metabolism in postmenopausal women with breast cancer.
    Bird CE; Masters V; Sterns EE; Clark AF
    Clin Invest Med; 1985; 8(2):97-102. PubMed ID: 2938865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in serum estrogen levels in women during tamoxifen therapy.
    Lum SS; Woltering EA; Fletcher WS; Pommier RF
    Am J Surg; 1997 May; 173(5):399-402. PubMed ID: 9168075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of estrone, estradiol, and estriol on hormone-responsive human breast cancer in long-term tissue culture.
    Lippman M; Monaco ME; Bolan G
    Cancer Res; 1977 Jun; 37(6):1901-7. PubMed ID: 870192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of tamoxifen on the serum levels of oestrogens and adrenocortical steroids in postmenopausal breast cancer patients.
    Wilking N; Carlström K; Sköldefors H; Theve NO; Wallgren A
    Acta Chir Scand; 1982; 148(4):345-9. PubMed ID: 6215811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary excretion of estrone, estradiol, and estriol in postmenopausal women with primary breast cancer.
    Morreal CE; Dao TL; Nemoto T; Lonergan PA
    J Natl Cancer Inst; 1979 Nov; 63(5):1171-4. PubMed ID: 291747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma levels of estrone, estrone sulfate, and estradiol and the percentage of unbound estradiol in postmenopausal women with and without breast disease.
    Reed MJ; Cheng RW; Noel CT; Dudley HA; James VH
    Cancer Res; 1983 Aug; 43(8):3940-3. PubMed ID: 6683128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen replacement therapy after the menopause. Estrogenicity and metabolic effects.
    Helgason S
    Acta Obstet Gynecol Scand Suppl; 1982; 107():1-29. PubMed ID: 6282033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormal estrogen conjugation in women at risk for familial breast cancer at the periovulatory stage of the menstrual cycle.
    Fishman J; Bradlow HL; Fukushima DK; O'Connor J; Rosenfeld RS; Graepel GJ; Elston R; Lynch H
    Cancer Res; 1983 Apr; 43(4):1884-90. PubMed ID: 6831424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of diet on excretion of estrogens in pre- and postmenopausal women.
    Goldin BR; Adlercreutz H; Dwyer JT; Swenson L; Warram JH; Gorbach SL
    Cancer Res; 1981 Sep; 41(9 Pt 2):3771-3. PubMed ID: 7260944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aminoglutethimide as an inducer of microsomal enzymes. Part 2: Endocrine aspects.
    Lønning PE; Kvinnsland S; Thorsen T; Ekse D
    Breast Cancer Res Treat; 1986; 7 Suppl():S77-82. PubMed ID: 3742065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steroid hormone profiles in women treated with aminoglutethimide for metastatic carcinoma of the breast.
    Samojlik E; Santen RJ; Kirschner MA; Ertel NH
    Cancer Res; 1982 Aug; 42(8 Suppl):3349s-3352s. PubMed ID: 7083199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
    Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
    Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen profiles of premenopausal women with breast cancer.
    Cole P; Cramer D; Yen S; Paffenbarger R; MacMahon B; Brown J
    Cancer Res; 1978 Mar; 38(3):745-8. PubMed ID: 626978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone replacement with estradiol: conventional oral doses result in excessive exposure to estrone.
    Friel PN; Hinchcliffe C; Wright JV
    Altern Med Rev; 2005 Mar; 10(1):36-41. PubMed ID: 15771561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
    Dixon JM; Renshaw L; Young O; Murray J; Macaskill EJ; McHugh M; Folkerd E; Cameron DA; A'Hern RP; Dowsett M
    J Clin Oncol; 2008 Apr; 26(10):1671-6. PubMed ID: 18375896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.
    Pasqualini JR; Chetrite GS
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):221-36. PubMed ID: 15860265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
    Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
    Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
    Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
    J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.